Current landscape of clinical trials for vitiligo: improving outcome standardization and trial diversity
Clin Exp Dermatol
.
2023 Jul 7;48(7):795-797.
doi: 10.1093/ced/llad097.
Authors
Kathleen M Mulligan
1
,
Katie A O'Connell
2
,
Madeline S Coleman
3
,
Alexandra da Silva
4
,
Minal Reddy
5
,
Lori Kim
6
,
Nagham Bazzi
7
,
Antara Afrin
8
,
Robert P Dellavalle
9
10
11
Affiliations
1
Case Western Reserve University School of Medicine, Cleveland, OH, USA.
2
Vanderbilt University Medical Center, Nashville, TN, USA.
3
College of Osteopathic Medicine, Edward Via College of Osteopathic Medicine, Blacksburg, VA, USA.
4
College of Medicine, California Northstate University, Elk Grove, CA, USA.
5
University of California, Irvine School of Medicine, Irvine, CA, USA.
6
University of Illinois at Chicago College of Medicine, Chicago, IL, USA.
7
Lebanese University Faculty of Medicine, Beirut, Lebanon.
8
College of Human Medicine, Michigan State University, East Lansing, MI, USA.
9
Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
10
Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
11
Dermatology Service, US Department of Veterans Affairs Rocky Mountain Regional Medical Center, Aurora, CO, USA.
PMID:
36916518
DOI:
10.1093/ced/llad097
No abstract available
MeSH terms
Humans
Hypopigmentation*
Treatment Outcome
Vitiligo* / drug therapy